The author discusses barriers to psychopahrmacological research,
including attacks by vocal human rights groups, regulation by local review
boards, and Department of Health, Education, and Welfare restrictions. He
suggests that those patients least able to give informed consent are most
in need of the benefits of research on new drugs.